Press Release: Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021
Press Release: Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021
Press Release: Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021
新聞稿:Xencor將於2021年2月23日主持2020年第四季度和全年財務業績網絡廣播和電話會議
Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021
Xencor將於2021年2月23日主持2020年第四季度和全年財務業績網絡廣播和電話會議
MONROVIA, Calif.--(BUSINESS WIRE)--February 16, 2021--
加利福尼亞州蒙羅維亞--(美國商業新聞網)--2021年2月16日--
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release fourth quarter and full year 2020 financial results after the market closes on Tuesday, February 23, 2021.
亞洲網加利福尼亞州聖何塞2月23日電Xencor公司(納斯達克市場代碼:XNCR)是一家臨牀階段的生物製藥公司,開發用於治療癌症和自身免疫性疾病的工程單克隆抗體和細胞因子。該公司今天宣佈,將在2021年2月23日(星期二)市場收盤後公佈2020年第四季度和全年的財務業績。
Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
Xencor管理層將在當天下午4:30主持網絡廣播和電話會議。美國東部時間(下午1:30)PT)討論財務結果並提供公司最新情況。
The live call may be accessed by dialing (877) 359-9508 for domestic callers or +1 (224) 357-2393 for international callers and referencing conference ID number 1163598. A live webcast of the conference call will be available online from the Investors section of the Company's website at www.xencor.com. The webcast will be archived on the company's website for 30 days.
可以通過撥打(877)359-9508(國內主叫方)或+1(224)357-2393(國際主叫方)並參考會議ID號碼1163598來接聽現場通話。電話會議的網絡直播可從公司網站www.xencor.com的投資者欄目在線收看。網絡直播將在公司網站上存檔30天。
About Xencor, Inc.
關於Xencor公司
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb(R) technology are in clinical development internally and with partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
Xencor是一家臨牀階段的生物製藥公司,開發用於治療癌症和自身免疫性疾病的工程化單克隆抗體和細胞因子。目前,由Xencor公司的XmAb(R)技術設計的20個候選藥物正在內部和與合作伙伴進行臨牀開發。Xencor的XmAb工程技術可以對蛋白質的結構進行微小的改變,從而產生新的治療作用機制。欲瞭解更多信息,請訪問www.xencor.com。
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216006095/en/
在business wire.com上查看源代碼版本:https://www.businesswire.com/news/home/20210216006095/en/
CONTACT: Charles Liles
聯繫人:查爾斯·萊爾斯(Charles Liles)
cliles@xencor.com
郵箱:cliles@xencor.com
Media Contact
媒體聯繫人
Jason I. Spark
傑森·I·斯帕克
Canale Communications
運河通信
619-849-6005
619-849-6005
jason@canalecomm.com
郵箱:jason@canalecomm.com
(END) Dow Jones Newswires
(完)道瓊通訊社
February 16, 2021 16:05 ET (21:05 GMT)
2021年2月16日東部時間16:05(格林尼治標準時間21:05)
譯文內容由第三人軟體翻譯。